Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) has extended the closing date of its Share Purchase Plan (SPP) to 5.00 pm (AEST) on Friday, July 25, 2025, following requests from shareholders for more time to participate. The extension provides additional time for eligible shareholders to apply for up to A$30,000 of new shares priced at A$0.040 each — a 16.7% discount to the 15-day volume weighted average price (VWAP) prior to the SPP announcement.
As a strong sign of support and confidence, all eligible directors have taken part in the SPP to date. The SPP is available to shareholders on record as of 7.00 pm (AEST) Monday, June 30, 2025.
The support is certainly justified. Prescient CEO James McDonnell spoke with Proactive following the launch of the company’s first clinical trial site for PTX-100 in the United States. Located at the Virginia Commonwealth University Cancer Center, the new site represents a key milestone in Prescient’s clinical expansion beyond its current footprint in Australia.
McDonnell emphasised that, due to the rarity of the disease targeted by PTX-100, broadening access to larger patient populations is essential for the success of the trial.
Revised SPP timetable announced
Prescient has updated key dates for the SPP. The plan was first announced on July 1, 2025, and opened the following day. Under the revised schedule:
Shareholders can request an electronic copy of their personalised Share Purchase Plan application form be emailed to them from the below link: https://prescienttherapeutics.investorportal.com.au/share-purchase-plan-opportunity-request/
Investor briefing and support
Chief executive officer James McDonnell will host an investor briefing on Tuesday, July 22, at 11.00 am (AEST) to discuss the recent initiation of Prescient’s first United States clinical trial site — a milestone towards a potential Phase 2b registrational study.
Register here: https://prescienttherapeutics.investorportal.com.au/investor-briefing/
About Prescient Therapeutics
Prescient is a clinical-stage oncology company focused on personalised cancer treatments. Its portfolio includes:
- PTX-100: a first-in-class inhibitor of GGT-1, targeting oncogenic Ras pathways in T-cell lymphomas. It has secured US Food and Drug Administration (FDA) Orphan Drug and Fast Track designations, with a Phase 2 study currently recruiting.
- CellPryme-M and CellPryme-A: novel technologies aimed at enhancing the performance and durability of adoptive cell therapies such as CAR-T by modifying T-cell behaviour and overcoming tumour microenvironments.
- OmniCAR: a universal immune receptor platform allowing post-infusion control and multi-antigen targeting through a modular CAR system, currently in pre-clinical development.